Cargando…

Serum-derived piR-hsa-164586 of extracellular vesicles as a novel biomarker for early diagnosis of non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is a major cause of death in those with malignant tumors. To achieve the early diagnosis of NSCLC, we investigated serum-derived Piwi-interacting RNA (piRNA) of extracellular vesicles to filter diagnostic biomarkers for NSCLC. High-throughput sequencing from cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yanli, Dong, Yanhan, Zhao, Shupeng, Gao, Jinning, Hao, Xiaodan, Wang, Zibo, Li, Meng, Wang, Mengyuan, Liu, Yiming, Yu, Xiaoling, Xu, Wenhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559724/
https://www.ncbi.nlm.nih.gov/pubmed/36249068
http://dx.doi.org/10.3389/fonc.2022.850363
_version_ 1784807694640611328
author Li, Yanli
Dong, Yanhan
Zhao, Shupeng
Gao, Jinning
Hao, Xiaodan
Wang, Zibo
Li, Meng
Wang, Mengyuan
Liu, Yiming
Yu, Xiaoling
Xu, Wenhua
author_facet Li, Yanli
Dong, Yanhan
Zhao, Shupeng
Gao, Jinning
Hao, Xiaodan
Wang, Zibo
Li, Meng
Wang, Mengyuan
Liu, Yiming
Yu, Xiaoling
Xu, Wenhua
author_sort Li, Yanli
collection PubMed
description Non-small cell lung cancer (NSCLC) is a major cause of death in those with malignant tumors. To achieve the early diagnosis of NSCLC, we investigated serum-derived Piwi-interacting RNA (piRNA) of extracellular vesicles to filter diagnostic biomarkers for NSCLC. High-throughput sequencing from cancerous tissues and adjacent noncancerous tissues in patients with NSCLC was first applied to recognize candidate piRNAs as diagnostic biomarkers. These screened piRNAs were further validated in 115 patients (including 95 cases in stage I) and 47 healthy individuals using quantitative real-time PCR (qRT-PCR). We showed that piR-hsa-164586 was significantly upregulated compared with paracancerous tissues and extracellular vesicles from the serum samples of healthy individuals. Moreover, the area under the curve (AUC) value of piR-hsa-164586 was 0.623 and 0.624 to distinguish patients with all stages or stage I of NSCLC, respectively, from healthy individuals. The diagnostic performance of piR-hsa-164586 was greatly improved compared with the cytokeratin-19-fragment (CYFRA21-1). Additionally, piR-hs-164586 was associated with the clinical characteristics of patients with NSCLC. Its expression was associated with the age and TNM stage of patients with NSCLC, indicating that it can serve as an effective and promising biomarker for the early diagnosis of NSCLC.
format Online
Article
Text
id pubmed-9559724
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95597242022-10-14 Serum-derived piR-hsa-164586 of extracellular vesicles as a novel biomarker for early diagnosis of non-small cell lung cancer Li, Yanli Dong, Yanhan Zhao, Shupeng Gao, Jinning Hao, Xiaodan Wang, Zibo Li, Meng Wang, Mengyuan Liu, Yiming Yu, Xiaoling Xu, Wenhua Front Oncol Oncology Non-small cell lung cancer (NSCLC) is a major cause of death in those with malignant tumors. To achieve the early diagnosis of NSCLC, we investigated serum-derived Piwi-interacting RNA (piRNA) of extracellular vesicles to filter diagnostic biomarkers for NSCLC. High-throughput sequencing from cancerous tissues and adjacent noncancerous tissues in patients with NSCLC was first applied to recognize candidate piRNAs as diagnostic biomarkers. These screened piRNAs were further validated in 115 patients (including 95 cases in stage I) and 47 healthy individuals using quantitative real-time PCR (qRT-PCR). We showed that piR-hsa-164586 was significantly upregulated compared with paracancerous tissues and extracellular vesicles from the serum samples of healthy individuals. Moreover, the area under the curve (AUC) value of piR-hsa-164586 was 0.623 and 0.624 to distinguish patients with all stages or stage I of NSCLC, respectively, from healthy individuals. The diagnostic performance of piR-hsa-164586 was greatly improved compared with the cytokeratin-19-fragment (CYFRA21-1). Additionally, piR-hs-164586 was associated with the clinical characteristics of patients with NSCLC. Its expression was associated with the age and TNM stage of patients with NSCLC, indicating that it can serve as an effective and promising biomarker for the early diagnosis of NSCLC. Frontiers Media S.A. 2022-09-28 /pmc/articles/PMC9559724/ /pubmed/36249068 http://dx.doi.org/10.3389/fonc.2022.850363 Text en Copyright © 2022 Li, Dong, Zhao, Gao, Hao, Wang, Li, Wang, Liu, Yu and Xu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Yanli
Dong, Yanhan
Zhao, Shupeng
Gao, Jinning
Hao, Xiaodan
Wang, Zibo
Li, Meng
Wang, Mengyuan
Liu, Yiming
Yu, Xiaoling
Xu, Wenhua
Serum-derived piR-hsa-164586 of extracellular vesicles as a novel biomarker for early diagnosis of non-small cell lung cancer
title Serum-derived piR-hsa-164586 of extracellular vesicles as a novel biomarker for early diagnosis of non-small cell lung cancer
title_full Serum-derived piR-hsa-164586 of extracellular vesicles as a novel biomarker for early diagnosis of non-small cell lung cancer
title_fullStr Serum-derived piR-hsa-164586 of extracellular vesicles as a novel biomarker for early diagnosis of non-small cell lung cancer
title_full_unstemmed Serum-derived piR-hsa-164586 of extracellular vesicles as a novel biomarker for early diagnosis of non-small cell lung cancer
title_short Serum-derived piR-hsa-164586 of extracellular vesicles as a novel biomarker for early diagnosis of non-small cell lung cancer
title_sort serum-derived pir-hsa-164586 of extracellular vesicles as a novel biomarker for early diagnosis of non-small cell lung cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559724/
https://www.ncbi.nlm.nih.gov/pubmed/36249068
http://dx.doi.org/10.3389/fonc.2022.850363
work_keys_str_mv AT liyanli serumderivedpirhsa164586ofextracellularvesiclesasanovelbiomarkerforearlydiagnosisofnonsmallcelllungcancer
AT dongyanhan serumderivedpirhsa164586ofextracellularvesiclesasanovelbiomarkerforearlydiagnosisofnonsmallcelllungcancer
AT zhaoshupeng serumderivedpirhsa164586ofextracellularvesiclesasanovelbiomarkerforearlydiagnosisofnonsmallcelllungcancer
AT gaojinning serumderivedpirhsa164586ofextracellularvesiclesasanovelbiomarkerforearlydiagnosisofnonsmallcelllungcancer
AT haoxiaodan serumderivedpirhsa164586ofextracellularvesiclesasanovelbiomarkerforearlydiagnosisofnonsmallcelllungcancer
AT wangzibo serumderivedpirhsa164586ofextracellularvesiclesasanovelbiomarkerforearlydiagnosisofnonsmallcelllungcancer
AT limeng serumderivedpirhsa164586ofextracellularvesiclesasanovelbiomarkerforearlydiagnosisofnonsmallcelllungcancer
AT wangmengyuan serumderivedpirhsa164586ofextracellularvesiclesasanovelbiomarkerforearlydiagnosisofnonsmallcelllungcancer
AT liuyiming serumderivedpirhsa164586ofextracellularvesiclesasanovelbiomarkerforearlydiagnosisofnonsmallcelllungcancer
AT yuxiaoling serumderivedpirhsa164586ofextracellularvesiclesasanovelbiomarkerforearlydiagnosisofnonsmallcelllungcancer
AT xuwenhua serumderivedpirhsa164586ofextracellularvesiclesasanovelbiomarkerforearlydiagnosisofnonsmallcelllungcancer